The outcomes of the trial confirmed that no less than 75% of sufferers with NSCLC harboring driver gene alterations could profit from this remedy.
Investigators discovered that an adaptive de-escalation tyrosine kinase inhibitor (TKI) technique could also be possible for sufferers with superior non–small cell lung most cancers (NSCLC) with no lesions after native consolidative remedy (LCT) and a unfavorable circulating tumor DNA (ctDNA) take a look at, in keeping with findings from a nonrandomized, exploratory proof of idea examine (NCT03046316) revealed in JAMA Oncology.
The outcomes of the examine discovered that no less than 75% of sufferers with NSCLC harboring driver gene alterations may benefit from this remedy. The median progression-free survival (PFS) was 18.4 months (95% CI, 12.6-24.2). Moreover, PFS charges at 12 and 24 months have been 67.7% (95% CI, 53.3%-78.5%) and 40.2% (95% CI, 24.3%-55.6%), respectively.
Amongst 60 sufferers identified with lung adenocarcinoma with driver gene-sensitive variations, all had acquired TKI earlier than enrollment. Fifty acquired first-line TKI remedy, and 10 acquired second-line remedy.
All sufferers had acquired no less than 1 remedy break by the closing date of November 30, 2022. Median follow-up time after remedy cessation was 19.2 months (vary, 3.8-29.7), and information analyses have been carried out from December 15, 2022 to Might 10, 2023 utilizing IBM SPSS Statistics.
The first finish level of the examine was PFS. Secondary finish factors included goal response price (ORR), time to subsequent remedy (TTNT), and total survival (OS).
The median complete remedy break length was 9.1 months (vary, 1.5-28.1). Three end result teams have been noticed primarily based on triggers of first retreatment; group A was composed of 14 sufferers who remained in remedy break, group B was composed of 31 sufferers who started retreatment after displaying optimistic molecular indicators earlier than progressive illness, and group C was composed of 15 sufferers who skilled confirmed illness development and reinitiated remedy.
Group A had a median remedy break of 20.3 months (vary, 6.8-28.1). Of the 31 sufferers in group B, 12 skilled development in subsequent retreatment (n = 3) or break intervals (n = 9), and median PFS was 20.2 months (95% CI, 12.9-27.4). The median PFS was 5.5 months (95% CI, 1.5-7.2) in Group C; among the many 15 sufferers, ctDNA was undetectable in 9, with 6 sufferers completely having mind metastases.
By the top of the examine interval, 27 sufferers had skilled illness development. Of those sufferers, 24 had a response to retreatment following prior TKIs. Twelve achieved a whole response, 11 achieved a partial response, and 1 had steady illness, yielding an ORR of 96% (95% CI, 87.7%-100%).
Twelve sufferers skilled illness development whereas receiving TKI retreatment and acquired physician-administered next-line remedy. The median TTNT from the initiation of the primary remedy break was 29.3 months (95% CI, 25.3-35.2). TNTT charges at 12 and 24 months have been 92.2% (95% CI, 80.2%-97.0%) and 74.1% (95% CI, 56.2%-85.5%), respectively.
Though no affected person died throughout remedy discontinuation, median OS information have been immature. Twelve of 24 sufferers who achieved adequate tumor regression opted to discontinue TKI remedy. In group B, ctDNA was undetectable in 96% of sufferers (n = 25), and carcinoembryonic antigens (CEA) reached a traditional stage in 3 of 5 sufferers after 3-month retreatment with prior TKI brokers.
Grade 1 to 2 antagonistic results (AEs) included rash (n = 7), paronychia (n = 2) and arrhythmia (n = 1). No grade 3 or worse occasions occurred.
Of those that skilled progressive illness (n = 27), 9 developed intrathoracic metastases, 11 had extrathoracic metastases, and seven developed each. Three sufferers underwent a second wedge resection for rising oligometastatic nodules within the lungs, and one other affected person acquired rib radiotherapy domestically. Twelve sufferers finally skilled development whereas receiving retreatment with prior TKIs and have been instructed to provoke next-line remedy; 7 acquired third-generation EGFR TKIs, 4 acquired chemotherapy, and 1 acquired erlotinib (Tarceva) together with bevacizumab (Avastin).
Reference
Dong S, Wang Z, Zhang JT, et al. Circulating tumor DNA-guided de-escalation focused remedy for superior non−small cell lung most cancers: a nonrandomized medical trial. JAMA Oncol. Printed on-line June 13, 2024. doi:10.1001/jamaoncol.2024.1779
